Clinical Trial Center - Academic Clinical Research Operating & Supporting System

Chungnam National University Hospital

Alopecia Areata

Alopecia

Baricitinib

LY3009104

Lilly

condition

allSponsorName

Incyte

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the treatment of severe or very severe alopecia areata. An additional subpopulation of 60 participants in the US will enroll in the open-label addenda.

A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata

Chungnam National University Hospital | Clinical Trial Center - Academic Clinical Research Operating & Supporting System

Site insights

Work at this site?

Active trials

A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata (BRAVE-AA1)

Trial sponsors